



The 65th ASH Annual Meeting Abstracts

POSTER ABSTRACTS

623.MANTLE CELL, FOLLICULAR, AND OTHER INDOLENT B CELL LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL**Time to Lymphoma Treatment within 24 Months in Watchful Waiting Follicular Lymphoma Defines Patients at High Risk for Progression: A Multicenter Analysis**

Fenghua Gao¹, Jing Liu¹, Jiesong Wang¹, Lihong Liu², Zhiming Li³, Yuqin Song, MD⁴, Xudong Zhang⁵, Hui Zhou⁶, Xiuhua Sun⁷, Wei Zhang⁸, Bing Xu⁹, Liping Su¹⁰, Wen Shujuan¹¹, Rong Tao, MD PhD¹², Ou Bai, MD PhD¹³, Qingyuan Zhang¹⁴, Liqun Zou, MD PhD¹⁵, Xianhuo Wang¹, Huilai Zhang¹⁶

¹Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

²The Fourth Hospital of Hebei Medical University, Shijiazhuang, China

³State Key Laboratory of Oncology in South China, Guangzhou, China

⁴Department of Lymphoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, BEIJING, China

⁵The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

⁶Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China

⁷The Second Hospital of Dalian Medical University, Dalian, China

⁸Peking Union Medical College Hospital, Beijing, China

⁹The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen, China

¹⁰Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Taiyuan, CHN

¹¹Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China

¹²Fudan University Shanghai Cancer Center, Shanghai, China

¹³Department of Hematology, The First Hospital of Jilin University, Changchun, China

¹⁴Harbin Medical University Cancer Hospital, Harbin, China

¹⁵West China Hospital of Sichuan University, Chengdu, China

¹⁶Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China

Purpose Follicular lymphoma (FL) is a clinically and molecularly heterogeneous disease, watch and wait (W&W) remains a management therapeutic option in patients with advanced-stage, low-tumor-burden and asymptomatic FL in the rituximab era. We continue to use Groupe d'Etudes des Lymphomes Folliculaires criteria for active disease to initiate therapy. We sought to understand whether time to lymphoma treatment (TLT) after diagnosis in patients who managed by W&W was a factor affecting survival outcomes in FL.

Patients and Methods Between 2008 and 2022, 411 FL patients from 16 institutions in China were managed by W&W strategy, and their TLT was retrospectively evaluated. Patients were further divided into training and validation Cohorts. Logistic regression was used to identify and incorporate independent predictors of early TLT into a model with variable scoring. Model performance was evaluated through the area under the receiver operating characteristic curve (AUC) and goodness-of-fit statistics.

Results After a median follow-up of 46 months, 35 percent of W&W patients experience TLT within 24 months (TLT24) after diagnosis, and the 5-year progression free survival (PFS) rate was significantly lower than that of patients who were treatment-free at 24 months (62.3% vs. 89.5%). In multivariable analysis, five clinical factors were identified as independent predictors of TLT24: stage III-IV, β_2 microglobulin $\geq 3\text{mg/L}$, lymphocyte-to-monocyte ratio < 3.8 , bone marrow involved and spleen enlargement. We calculated risk scores (TLT24PI) for each patient and defined three risk groups: low (0-1 points), intermediate (2 points), or high (3-5 points). Its AUC for TLT24 was 0.761 (95% CI, 0.698 - 0.823) in the development cohort and 0.761 (95% CI, 0.698 - 0.823) in the validation cohort. Risk groups were also associated with PFS ($P < 0.001$).

Conclusion In patients with FL who initially managed by W&W, TLT within 24 months after diagnosis was associated with poor outcomes. We developed a multivariable model that incorporates clinical and laboratory factors to identify patients at high risk for TLT24, which may be useful to identify candidates for early interventional treatment.

Disclosures No relevant conflicts of interest to declare.




Figure 1

<https://doi.org/10.1182/blood-2023-174308>